RSV Seasonal Vaccine Introduction and Growth Strategy

Changes since Q1 2023 Changes on pipeline New to Phase II 4348413 - GMMA, gonorrhea 3858279 Anti-CCL17 antibody, osteoarthritis pain ** Achieved pipeline catalysts Regulatory submissions & acceptances Jemperli - RUBY, dMMR/MSI-H IL endometrial cancer Menveo - liquid formulation, Men ACWY New to Phase III ibrexafungerp - Antifungal glucan synthase inhibitor, invasive candidiasis camlipixant - P2X2/P2X3 receptor antagonist, refractory chronic cough Regulatory decisions Arexvy - Adjuvanted recombinant protein, RSV older adults Shingrix 18+ at increased risk of HZ Removed from Registration SKYCovione - Recombinant protein nanoparticle, adjuvanted, COVID-19 daprodustat - Prolyl hydroxylase inhibitor, anaemia of chronic kidney disease GSK ** Additional indications or candidates also under investigation 1. Tesaro asset Other events Infectious diseases HIV (VIIV) Respiratory/Immunology Oncology Opportunity driven US EU JP SS US, EU - MenABCWY Phase III data presentation at ESPID 4348413 - GMMA, gonorrhea - FDA Fast Track Designation cabotegravir (long-acting) pre-exposure Positive CHMP opinion - 3858279 - Anti-CCL17 antibody, osteoarthritis pain - FDA Fast Track Designation 3858279 - Anti-CCL17 antibody, diabetic peripheral neuropathic pain - FDA Fast Track Designation Jemperli - RUBY, dMMR/MSI-H 1L endometrial cancer - FDA Priority Review Jemperli - RUBY, DMMR/MSI-H IL endometrial cancer FDA Breakthrough Designation daprodustat - Positive CHMP opinion 40

View entire presentation